Common clinical indications

• Treatment of cystic fibrosis in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene or who have at least one CFTR mutation that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Frequently asked questions

What is Tezacaftor and Ivacaftor used for?

Tezacaftor and Ivacaftor (Tezacaftor and ivacaftor) is listed in YMed Atlas under Cystic fibrosis transmembrane conductance regulator corrector and potentiator. Indications, dosing, and safety information on this page summarize curated references—always confirm with current labeling, formularies, and local protocols.

How do I adjust dosing for renal impairment or special populations?

Review the dosing sections and references for this monograph. Many agents require renal or hepatic adjustment; pediatric, pregnancy, and lactation considerations are clinician-specific. This interface is educational and does not replace individualized prescribing decisions.

Is this medical advice?

No. YMed Atlas drug pages support learning and quick reference. They are not a substitute for clinical judgment, pharmacist review, or formal interaction checking with a complete medication list.